
Triple-receptor agonist · 30mg formulation
Maximum-dose Retatrutide — the advanced tier for clients who have progressed through the full Lumeva step-up programme.
Advanced maximum-dose triple-receptor agonist for established protocol clients, providing full GLP-1, GIP, and glucagon pathway engagement.
The RT30 Protocol represents the pinnacle of the Lumeva Retatrutide programme. At 30mg, it delivers maximum triple-receptor agonist engagement — reserved for clients with a fully established protocol history and confirmed suitability.
Clients reaching RT30 have typically progressed through RT10 and RT20 under expert guidance, with regular biomarker monitoring confirming their readiness for the advanced dose tier.
The RT30 Protocol is not an entry point. It is the destination for those committed to the full Lumeva Method metabolic programme, guided every step of the way by our expert team.
Every Lumeva protocol is manufactured using advanced synthesis techniques within controlled laboratory environments. Carries ≥99.9% purity certification and full batch-specific QA documentation.
Confirm your readiness with a consultation before proceeding to the RT30 advanced formulation.